FDA granted accelerated approval for Lynozyfic, and J.P. Morgan reiterated a Buy rating for the company.
4 reports, 1 independent
Updated Jul 11
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted accelerated approval for Lynozyfic, and J.P. Morgan reiterated a Buy rating for the company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA granted accelerated approval for Lynozyfic, and J.P. Morgan reiterated a Buy rating for the company.1 source
- Regeneron's Lynozyfic approval places it in competition with Johnson & Johnson in MM treatment.
Keep exploring
The entities involved
- FDA
-
Regeneron Pharmaceuticals
American pharmaceutical company
-
J.P. Morgan & Co.
U.S. investment bank
Nothing else this week.
- FDA
Related events
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- The FDA recommended advancement for a new drug application submitted by a company.
Coverage
Newest first; wire copies grouped- Insider MonkeyRegeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company sec
- Unknown outlet
- Unknown outlet
- Unknown outlet